Massachusetts Institute of Technology

Beth Israel Deaconess Medical Center, Inc.

Whitehead Institute for Biomedical Research

Joslin Diabetes Center, Inc.

Beth Israel Hospital

Benjamin G Neel

Harvey F Lodish

Robert D Rosenberg

Steven E Shoelson

Stephen Michnick

Ursula Klingmuller

Ulrike Lorenz

Scott Pluskey

Jorge Plutzky

Alana M O'Reilly

Robert M Freeman, Jr

The invention relates to novel mutant SH2 domain containing protein tyrosine phosphatases wherein the phosphatase is partially or constitutively active; and whose ability to regulate biological processes are different from the wildtype protein tyrosine phosphatases. The invention also relates to methods of use of the novel mutants, for example, in in vitro assays to screen for binding partners and inhibitors of protein tyrosine phosphatases and in the treatment of protein tyrosine phosphatase mediated diseases or conditions.

Activated mutants of SH2-domain-containing protein tyrosine phosphatases

Novel assays for identifying agents which alter the effect of erythropoietin on proliferation of erythroid cells and agents identified thereby. Novel peptide comprising the erythropoietin receptor binding site for SH-PTP1.

Peptide which binds SH.sub.2 domains of protein tyrosine phosphatase

The present invention relates to the isolation of genes encoding novel protein tyrosine phosphatases (PTPs) having SH2 domains, the nucleic acid sequences isolated, and the encoded phosphatases. The invention further relates to methods of altering tyrosine phosphatase activities encoded by the novel phosphatases. By altering (i.e., increasing or decreasing) tyrosine phosphatase activity, one can alter megakaryocyte cell function, and thereby alter platelet production. Alteration of the genes is associated with neoplastic disease.

Methods for identifying a tyrosine phosphatase abnormality associated

Growing community of inventors

Wayland, MA, United States of America

Benjamin G Neel